One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for ...

Randomized clinical trials remain the gold standard for establishing a medication's effects, producing the evidence by which ...

GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today announced that it has dosed the first patient in its global ...

World-leading challenge study expertise helping deliver scalable, high-quality outpatient vaccine trials in healthy ...

First patients dosed in budoprutug PrisMN Phase 2 trial in pMN, with initial data expected second half 2026 Dosing ongoing in ...

Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment ...

Traditional trial start-up workflows often follow a sequential path, from feasibility to contracting, then regulatory ...